Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZT006 in Overweight and Obese Participants
NCT07230132Phase 2Active, not recruiting
- Sponsor
- QL Biopharm
- Start
- Dec 2025
- Primary completion
- Dec 2026
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ZT006 in obesity (6 arms), sponsored by QL Biopharm. Primary endpoints: Change in body weight relative to baseline at 28 weeks, Rate of treatment-emergent adverse events in the extension period at 45 weeks and 1 more. Started Dec 2025; status: active, not recruiting.
02
Drugs
ZT006
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07230132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07230132.